Welcome to our dedicated page for BioRegenx news (Ticker: BRGX), a resource for investors and traders seeking the latest updates and insights on BioRegenx stock.
BioRegenx, Inc. (BRGX) is a health-technology and health information services company focused on microvascular, metabolic, and cellular health through patented diagnostics, nutraceuticals, and AI-powered digital health technologies. The BRGX news page highlights company announcements related to technology development, corporate strategy, and capital markets activity.
Readers can find updates on BioRegenx 27s key platforms, including the GlycoCheck ae vascular diagnostic system and the DocSun AI-driven, non-contact vital-sign detection technology. News coverage includes information about licensing agreements, such as the exclusive worldwide distribution license for GlycoCheck ae, as well as details on how data from these systems supports the company 27s analytics infrastructure for microvascular and metabolic-health insights.
The news feed also features items on corporate milestones, including mergers, subsidiary integration, auditor transitions, and legal and advisory engagements. For example, BioRegenx has reported on its acquisition and integration of DocSun Biomedical Holdings, its engagement of a new PCAOB-registered independent auditor, and its retention of Sichenzia Ross Ference Carmel LLP to advise on a planned uplisting to a senior national securities exchange.
Investors and observers can use this page to follow developments in AI-based non-contact vital-sign monitoring, vascular diagnostics, and the company 27s broader strategy to commercialize its technologies and pursue capital markets objectives. The news archive offers context on how BioRegenx positions itself within digital health, biotechnology, and health information services.
BioRegenx (OTC: BRGX) announced a series of corporate and technology milestones on Dec 9, 2025. Key actions include engaging a new PCAOB-registered auditor, finalizing an exclusive worldwide license for the clinically validated GlycoCheck vascular diagnostic system, completing integration of the DocSun AI non-contact vital-sign platform, and engaging an investment bank to pursue planned 2026 initiatives.
GlycoCheck is supported by 147 peer-reviewed studies and generates recurring revenue for the company; DocSun provides an SDK and has executed multiple LOIs to explore third-party integrations. The company said it aims to combine GlycoCheck clinical data with DocSun AI to develop predictive vascular and metabolic-health analytics while noting no assurances on regulatory approvals or commercialization outcomes.